Corvus Pharmaceuticals is a healthcare company focused on developing immuno-oncology therapies for cancer treatment. Its core products include investigational drugs targeting specific cancer pathways, with a primary emphasis on enhancing the immune response against tumors. The company operates in the biotechnology segment, primarily generating revenue through research and development activities and potential future product sales.
The investment profile of Corvus Pharmaceuticals is more aligned with growth investors, given its focus on developing innovative therapies in a high-risk sector. The lack of dividends and the company's current financial performance suggest a higher risk profile, making it less suitable for conservative investors. The stock may appeal to those with a longer investment horizon who are willing to accept volatility for potential future gains.
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-06-03 02:37 | Hold | Sell | scenario_deterioration |
| 2026-06-01 02:35 | Sell | Hold | Weak fundamentals and negative momentum signal high risk. |
| 2026-05-16 02:54 | Hold | Sell | scenario_deterioration |
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-04-17 08:42 | Goldman Sachs | Update | — → 40 | 15.04 |
| 2026-01-29 11:45 | Mizuho Securities | Target Raised | 20 → 30 | 20.54 |
| 2026-01-22 17:28 | Jefferies | Target Raised | 13 → 42 | 25.8 |
